Noumed Pharmaceuticals, the Australian subsidiary of UK-based pharmaceutical company Noumed Life Sciences, is developing a new manufacturing plant in Adelaide, South Australia (SA). The development marks the company’s inaugural production facility in the country. The facility is designed to produce a range of over-the-counter (OTC) pharmaceuticals for the local market.
The project will provide Noumed’s customers with enhanced supply chain efficiency, including reduced lead times while catering to specific market demands more responsively. Noumed is investing approximately A$100m ($65.6m) in the new facility.
The ground-breaking ceremony for the facility was held in February 2024, with the opening of the plant anticipated in 2026. The construction phase is expected to generate 250 jobs. The facility will offer 180 permanent positions in various fields, including pharmacy, science, engineering, and logistics, upon completion.
Location The new plant is situated within Nexus North Industrial Estate, a master-planned industrial park at Level 3, 89 Pirie Street, Adelaide, SA. The estate is owned and developed by Terre Property Partners, a property development and investment manager. It is set to host a mix of national and international companies, including Asahi, Telstra, Haighs Chocolates, and FJT Logistics.
Noumed’s pharmaceutical manufacturing facility details Noumed’s pharmaceutical manufacturing facility will span an area of 43,000m2 with a building floor space of 26,0.